日本語 
A promising drug can spend years in development, yet its clinical trial can struggle to move forward because researchers cannot find enough eligible patients. This is a problem the pharmaceutical and medical device industries continue to face. Traditional recruitment depends heavily on hospital referrals, manual record reviews and predefined screening criteria. As a result, eligible patients can remain unidentified even when relevant clinical information already exists in their records. AI-powered clinical trial matching is changing how researchers approach this challenge. However, its real value depends on how accurately it interprets patient data, evaluates eligibility and supports clinical decisions.
How AI Clinical Trial Matching Actually Works Under the Hood
Traditional patient screening largely depends on Boolean searches and predefined database queries. Researchers enter specific terms, diagnosis codes or combinations of medical conditions to identify potential candidates. However, this approach has a major limitation. It can find records containing the right keywords without understanding the patient’s complete medical history. A reference to chemotherapy, for instance, does not establish when treatment occurred or whether it makes someone ineligible for a particular study.
AI-powered clinical trial matching takes a more contextual approach. Natural language processing (NLP), Named Entity Recognition (NER) and machine learning help systems identify medical conditions, treatments, medications and their relationships within clinical documents. Microsoft’s Text Analytics for Health, for example, processes clinical notes and trial protocols using entity recognition, relation extraction, assertion detection and entity linking. This allows systems to distinguish between a confirmed diagnosis, a ruled-out condition and a historical treatment record. Microsoft’s technical documentation explains these capabilities.
More importantly, modern systems can examine information beyond structured ICD-10 codes. Pathology reports, physician notes, genomic findings and imaging summaries may contain details that standard database searches overlook. Large Language Models (LLMs) can interpret this context, while retrieval-augmented generation (RAG) retrieves relevant source information before generating an assessment. This helps ground the output in actual clinical records rather than relying entirely on the model’s generated response.
Google’s BigQuery architecture provides another useful example. Its clinical research scenario uses embedding generation, natural-language AI.SEARCH and hybrid search across thousands of clinical trial documents. By combining semantic retrieval with exact keyword matching, the system can identify related medical concepts while retaining precision for technical identifiers. Google’s August 2026 publication describes this approach.
The next step is eligibility assessment. Consider a trial that excludes patients who received chemotherapy within the previous six months. The system must examine treatment history, identify relevant dates and compare them against the protocol’s requirements. It can then rank potential candidates according to their available evidence and match probability. However, a high match score should never be treated as confirmed eligibility. Missing information and uncertain clinical findings still require human review.
Measurable Impact on Recruitment Velocity and Research Outcomes
The traditional recruitment process often starts after a clinical trial site receives its protocol. Research coordinators then search hospital records, contact physicians and manually review patient histories. This makes recruitment slow and highly dependent on the capacity of individual research teams. AI-powered clinical trial matching creates an opportunity to reverse this process by identifying potential patient cohorts from existing clinical data before researchers begin outreach.
However, the size of a patient database does not necessarily determine how useful it is for recruitment. AWS shared an example involving Novo Nordisk, where researchers analysed 1,175 tokenised trial participants across four real-world data categories. In one category, 11% of participants had some relevant data available, but only 1% had records that were completely usable for the variables being examined. The finding exposed a significant gap between data coverage and data usability during trial feasibility assessment. AWS’s October 2026 clinical trials report discusses the example.
This distinction matters because identifying a patient is only the beginning. Researchers need sufficiently complete records to establish whether that patient meets the protocol’s requirements. Consequently, AI matching must account for data quality alongside recruitment speed.
The technology can also support more representative recruitment. Conventional referral networks may favour patients who visit large academic hospitals or already have access to specialist care. AI can widen the search by identifying eligible individuals across participating community clinics and different healthcare networks. Nevertheless, it does not automatically eliminate referral bias. The patient population represented in the underlying records, access to testing and quality of documentation still influence whom the system identifies.
Similarly, researchers can use historical patient data to examine whether exclusion criteria are unnecessarily restrictive before a trial begins. If particular requirements eliminate large portions of otherwise relevant patient cohorts, trial designers can review whether those restrictions are scientifically justified. This can help reduce avoidable screening failures and improve recruitment feasibility. However, better matching alone cannot guarantee patient retention. Trial complexity, treatment burden and the patient’s ability to continue participating remain important considerations.
Real-World Implementation and Integration into Clinical Workflows
Even an accurate matching system will struggle if it operates separately from the hospitals and clinical teams expected to use it. Patient records sit across different departments, EHR platforms and specialist systems. Therefore, interoperability becomes a central requirement for successful implementation.
Microsoft-commissioned OnePoll research published in September 2026 found that 97% of surveyed healthcare leaders reported that data silos already affect their ability to deliver timely care. The research covered 500 healthcare decision-makers across seven countries. Although this finding concerns healthcare more broadly, it highlights the data fragmentation that clinical research systems must address. Microsoft’s healthcare data research provides the findings.
Standards such as HL7 FHIR and SMART on FHIR help connect healthcare applications with existing clinical systems. Instead of requiring researchers to move between multiple databases, an integrated solution can surface relevant trial opportunities within an authorised clinician workflow. However, integration must be designed carefully. Too many alerts can interrupt consultations and create alert fatigue, causing clinicians to ignore even relevant recommendations.
AI-powered clinical trial matching should therefore work as a clinical decision-support co-pilot. AWS illustrates this through an architecture involving three specialised agents. One handles preliminary screening, another evaluates detailed eligibility criteria, and a third supports site and enrollment logistics. The system produces Eligible, Ineligible or Requires Review recommendations, supported by criterion-level evidence, confidence scores and citations to patient records. Clinicians retain final decision-making authority, while the workflow records actions through an audit trail. AWS’s August 2026 architecture explains the model.
Consider an oncology centre treating newly diagnosed non-small cell lung cancer (NSCLC) patients. During a tumour board review, the matching system could examine each patient’s diagnosis, disease stage, genomic findings and treatment history. It could then compare these records against biomarker-specific clinical trial protocols and flag relevant studies. The Clinical Research Coordinator (CRC) would review the supporting records, identify missing information and check whether the patient meets the preliminary requirements. Finally, the Principal Investigator (PI) would assess clinical suitability and oversee the next steps. The patient would only enter the study after the required consent and eligibility procedures.
This is where the technology becomes useful. It reduces the effort involved in finding potential candidates while keeping clinical judgement with the people responsible for patient care.
Trust, Governance and Regulatory Guardrails
Clinical records contain some of the most sensitive information a person shares with a healthcare provider. Consequently, AI-powered clinical trial matching must operate within strict privacy and security controls. This includes protecting Personally Identifiable Information (PII), safeguarding Protected Health Information (PHI) and controlling who can access patient records.
In the United States, HIPAA governs how covered entities and their business associates handle protected health information. Researchers and technology providers must establish appropriate safeguards when processing such data. De-identification can also reduce exposure when identifiable information is not required. The US Department of Health and Human Services recognises two methods under HIPAA, namely Expert Determination and Safe Harbor. However, removing obvious identifiers does not automatically eliminate every risk of re-identification. HHS de-identification guidance explains these requirements.
Similarly, GDPR applies to personal data processing within its relevant legal scope in the European Union. Organisations must establish an appropriate legal basis, protect sensitive information and respect applicable data subject rights. Meanwhile, zero-trust security architectures strengthen access control by requiring verification rather than assuming that users or systems are trustworthy simply because they operate within a hospital network.
Data security, however, addresses only part of the problem. AI models can misinterpret medical language, overlook important context or produce unsupported conclusions. Therefore, every recommendation should carry an explainable trail. Researchers should be able to see which eligibility criterion triggered a match, the exact clinical evidence supporting it and which requirements remain uncertain. This allows CRCs and PIs to challenge incorrect assessments rather than accepting an AI-generated score without question.
Algorithmic bias also requires continuous attention. A model trained predominantly on records from large urban hospitals may perform differently when processing documentation from smaller clinics or underrepresented patient populations. Consequently, organisations need to test model performance across different patient groups, monitor false matches and exclusions, and review changes in performance as clinical data evolves.
Regulatory alignment adds another layer of accountability. The FDA’s Good Machine Learning Practice (GMLP) principles emphasise safe, effective and high-quality development across the lifecycle of AI-enabled medical devices. The EU AI Act also establishes requirements for certain high-risk AI systems, including applicable medical-device-related AI. However, not every clinical matching application automatically falls into the same regulatory category. Its intended purpose and regulatory status matter. FDA’s GMLP principles and the EU AI Act provide the relevant foundations.
Ultimately, trust depends on whether a system can explain its recommendations, protect patient information and remain accountable when its assessments are wrong.
Also Read: UCB Expands CRM Capabilities With Veeva Vault
Conclusion
AI-powered clinical trial matching can make clinical research more responsive by connecting patient information with relevant research opportunities. Yet, the industry’s biggest challenge is not simply finding more candidates. It is building systems that can distinguish a possible match from a medically suitable participant.
The next phase will bring multimodal AI together with genomics, radiomics and longitudinal EHR data, while decentralized clinical trials could widen access beyond traditional research sites. Still, neither development removes the need for complete records, realistic protocols and clinical oversight. The real progress will come when research teams use AI to make better recruitment decisions, rather than simply making existing processes faster.
English